GSK chief wants Olympics lab to outlast games

GlaxoSmithKline has scored a slew of publicity on its Olympic drug-testing lab. Apparently, though, CEO Andrew Witty isn't satisfied with whatever image-boosting points GSK ($GSK) gains from the anti-doping facility. He wants to make drug testing a long-term profit center--but not for the drugmaker itself.

"What we're determined to do is to make sure that after the Olympics and after the Paralympics, this becomes a permanent business," Witty told the Telegraph. "This isn't a one-off phenomenon that gets thrown away."

GSK built up the laboratory at a plant in Harlow, England, with a team of more than 150 scientists charged with testing 400 samples a day for the games. During the Olympics, the lab will officially be run by the International Olympic Committee. By year's end, Witty hopes to determine whether this "cutting-edge test facility" could be sold or offloaded to a consortium to operate it on an ongoing basis.

"This has the potential to be a sustainable business, not a Glaxo business, but a sustainable business with permanent jobs created, which I think is very exciting," Witty told the Telegraph. "It doesn't have to just do drug tests for athletes. It could do other types of testing. There's a demand for that kind of thing, and we think this is absolutely deliverable as a sustainable business post-Games."

- here's the article

Suggested Articles

Regeneron and Sanofi hope their PD-1 inhibitor Libtayo will be the first immuno-oncology treatment approved to treat basal cell carcinoma.

With its phase 3 trial moving right along, Moderna is expecting efficacy data in November—likely after Pfizer and BioNTech, but before everyone else.

Pfizer, GSK, BIO and others are all planning vaccine messages for fall.